Interviewed by Sisterhood editorial board member Erika Smith, Nina Tandon describes what it has taken to get a startup through the recent difficult times for the biotech sector, including applying for military funding and making the product available in international markets where compassionate use is an option.

Interviewed by Sisterhood editorial board member Grace Colón, Dr. Gujrathi discusses a three pillar framework for success she has learned during her career in life sciences: know thyself, understand your environment, and set yourself up for success.

Interviewed by Sisterhood editorial board member Erika Smith, Reenie McCarthy discusses how working with the Barth Syndrome Community, an ultra rare disease, helped the company better understand outcomes that are important to daily life for these patients. She also highlights the role that mitochondria play in biology, and the future of treatments for diseases of mitochondrial dysfunction.

She describes the process of how the company's computing platform sorts through proteins that are secreted by stem cells and screens them for therapeutic potential. Plus, the lead clinical program for muscle conditions and also a partnership with Lilly in the obesity space.

She discusses the approach and the company's lead program, which targets PI3Kδ. Plus, and autotaxin program for cancer and TGF-β.

Dr. Gujrathi describes the beginning of the Sisterhood, discusses her new book, "The Mirror Effect," and shares her take on biotech and what types of companies and teams she likes to work with.

She describes the unmet need for patients who no longer respond to the large CDK4/6 class of medicines, and the decades of work she has put into solving the problem of adding CDK2 inhibition into the equation.

She describes the work the company is doing, which has a lead program targeting PIP4K2C and is scheduled to be in the clinic later this year.

Interviewed by Sisterhood editorial board member Sheila Gujrathi, Kiran Mazumdar-Shaw describes her beginnings in designing enzymes, and eventually pioneering biologics and biosimilars after an initial success in making recombinant human insulin for the India market. She discusses her emphasis on affordable innovation and shares business learnings from her career.

Interviewed by Xilio Therapeutics President & CEO René Russo, Dr. Liebisch describes her start in the industry as a patent attorney, discusses why having a champion in a larger partner is key, and explains why she even once threw a party when Vigil discontinued a candidate. Vigil Neuroscience was acquired by Sanofi earlier this year for an equity value representing approximately $470 million, plus a CVR.